View this email in your browser
June 25th 2019
General Assembly
Over one hundred people from across the world gathered at the project's General Assembly in June

“We’re in a unique position in the world” when it comes to biomarker research, said Eva Loth, Deputy Project Coordinator, at the annual meeting this month. Attendees mapped out the next steps in developing biomarkers to identify sub-groups of autistic people likely to benefit from a given treatment or support. Key to this development is better understanding the enormous diversity in autism, said Eva, and it is here that AIMS-2-TRIALS leads the way, with multidisciplinary data and many more participants than previous studies.

Researchers from different disciplines and locations enjoyed the rare opportunity to network
In a ground-breaking step, the consortium welcomed three Autism Representatives (A-Reps) to the meeting. The A-Reps spoke about their experiences, expertise and priorities for research. They told researchers that autistic people may need clearer explanations and more time to respond to questions. They also met the ethics board and advised them to consider 'person orientated ethics'.
People adopt the perspectives of others in a role playing game (left),
and discuss the latest research during the poster presentations (right)
The Early Career Researcher Autism Network launch saw over thirty researchers share ideas about their training needs. Join the conversation on slack and find out more by emailing Network leads Amber Ruigrok and Julian Tillman. Julian was one of several to be awarded a medal (below, left) at a humorous prize ceremony led by Declan Murphy, Project Co-Lead (right). Poster prizes were also awarded by A-Reps and the Scientific Advisory Board.
A Global Stage for Autism Research
The General Assembly built on discussions that began at INSAR, in Montreal (above) during May, and where AIMS-2-TRIALS had a strong presence. Opening the conference was Simon Baron-Cohen (below), the then President of INSAR and lead of our communications team. Simon spoke of the need to balance and integrate biological research with work on policy, education and support.
The potential of biomarkers to make personalised treatments a reality within the next decade was explored in a panel discussion led by Declan Murphy. Progress in the search for neuroimaging biomarkers was considered in a session chaired by Eva Loth. During this session, Dori Floris presented data from the LEAP study, which shows that brain hemispheres may be connected differently in autistic men and women.

Researchers from across AIMS-2-TRIALS were in action, presenting new data and meeting future collaborators. Early career researchers shone in the poster presentations (below), where the room was humming with questions and ideas.
Beth Oakley (left) discusses data on anxiety and depression in autism
with Hannah Meyer-Lindenberg, at INSAR 
In the Spotlight
Get your research into the headlines with the help of the communications team. Tell us as soon as your paper is accepted, to give us time to prepare any coverage, and remember to make all papers open access.
Early Career Training: Jan Buitelaar, Co-Lead of the biomarkers research, will lead a 'campfire' session to discuss the need for biomarkers in autism at the annual congress of the European College of Neuropsychopharmacology (ECNP) in September. You can share your research at the ECNP early career workshop in 2020. 

Vacancies: A post-doctoral research assistant to discover and validate EEG biomarkers, with Professor Grainne McAlona at King's College London (deadline: July 11th). Also at King's College London, a lecturer or senior lecturer in psychology (to be in post by September).

Do you have updates or notices to share in future newsletters? Let us know.
Copyright © 2019 AIMS-2-TRIALS, All rights reserved. 
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI.


This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
AIMS-2-TRIALS · Communications Team · University of Cambridge · Cambridge, Cam CB2 8AH · United Kingdom

Email Marketing Powered by Mailchimp